BioCryst Pharma (BCRX) Misses Q3 EPS by 3c

BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $3.77 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Exyn Technologies, Inc. (EXYN) Reports Q2 Loss of $1.55
• FOMC minutes from July 28-29th meeting